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ABSTRACT 
 
Collaborative Network (CN) has been the current clustering technology that embraces single and 
small firms to become large, vertical and horizontal enterprises for a decade now. This was predicted 
just after the formulation of the Electronic Market Hypothesis (EMH) which is popularly known as 
world-wide web (www) that businesses with common strategic goals will work closely together 
virtually. This is what is today known as the business-to-business (B2B). Organizations and 
enterprises are now taking the advantage of collaboration platforms to operate innovatively for 
competitive advantages and huge market shares in both local and international markets. This paper 
reviews the recent empirical studies on CNs as applied in the pharmaceutical industry. This review 
therefore revisits the core debates on CNs, its evolution, antecedents, prospects and challenges in 
collaboration. It ends by outlining prerequisite conditions of effective deployment of CN among 
pharmaceutical enterprises. There is an identification of Research and Developments (R&D) 
intermission in the pharmaceutical industry concerning concurrent engineering which should take 
place at the Pharma-biotech sector in the industry where R&D is carried out. It is now in a discovery 
that, Collaborative Networked Organizations (CNOs) use their virtual co-innovation platforms to 
support their R&D projects for rapid and simultaneous service-product innovations.  
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INTRODUCTION 
Nowadays, an ever increasing number of enterprises 
recognize and inspired to hold fast to synergistic 
platforms as business consent influences, enabling 
collaboration of companies to enhance their offer and 
competitiveness (Graca and Camarinha-Matos, 2017). 
The digital transformation of people’s daily life is 
progressing; almost everybody uses connected 
devices, shares information and builds a network 
according to the existing preferences or needs 
(Paulus-Rohmera et al, 2016). A comparable 
improvement happens in the modern condition. For 
instance, the Information Technology (IT) and 
software industry is now sorted out in profoundly 
connected ecosystems. The quick improvements of 
the information and communications technologies  
 
(ICT), permitting the advancement of collaborative 
platforms, enhancing larger firms' value chain and 
like the pharmaceutical industry which is complex 
(Raja and Sambandan, 2015), requires collaboration 
and pull in accomplices who have more prominent 
access to capital, more business contacts, better 
organizational capabilities, and comprehension of 
marketplace dynamics (Khulji et al. 2006; Petrova, 
2014). This time, however, the focus on mere 
product innovation is absolutely deficient for many 
enterprises (Nachira, 2002; Nachira et al., 2007; 
Paulus-Rohmera et al, 2016) but how parallel 
innovation ought to happen. In inter-firm 
collaborations, there are diverse strategic roles an 
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organization can play, which influences its business 
system. 
Pharmaceutical industry is a profoundly innovation 
driven industry which all through its history has 
added to the well-being of the people by giving new 
solutions to address different ailments and have 
developed into one of the significant segments in the 
world (WHO, 2015). Enterprises within 
pharmaceutical industry do completely coordinated 
pharmaceutical operations that incorporate research 
and development (R&D), manufacturing, clinical 
trials, administrative, marketing and sales (Hedner, 
2012). Modern drug innovation for the most part 
with complexities is taken care of with multi-level 
arrangement of self-organizing (Petrova, 2014) and 
collaborative interventions. The eventual success of 
the ecosystem to sustain pharmaceutical business 
transformation requires the entire organization to 
develop a high degree of maturity in the application 
of value network technologies to achieve strategic 
business goals (Zahra and Nambisan, 2012).  
The culture of encouraging entrepreneurship and 
innovation has been conducive to the creation of 
inter-firms collaborations. CN continues to develop 
exponentially and across many different industrial 
sectors simultaneously accelerating innovation and 
progress (Stegemann, 2016). Recent studies have 
empirically tested the influence of an OI related 
variables on inter-organizational collaboration, 
vertical integration and collaborative agreements, 
alliance formation and network perspectives. 
Marginal application challenges have been 
discovered in other CN studies. Hence stakeholders’ 
support and concurrent product innovation and 
development are to be introduced in pharmaceutical 
R&D and manufacturing endeavors.  
 
Relevant Studies Selection  
Literature on CNs and OIs is abundant and fast 
emerging. This study therefore, does not claim to 
have undertaken an exhaustive coverage of all 
relevant material. A Google search on the phrases 
“collaborative networks and open innovations”; 
“collaborative business ecosystems and industry 
clustering technologies” produced 36, 400, 000 and 
148, 000,000 results respectively on July 13
th
 2017. 
The paper primarily draws on a selection of peer 
reviewed publications in English language available 
online in two major academic article databases, 
namely; Elsevier (www.sciencedirect.com) and 
Springer (www.springerlink.com).  Relevant articles 
were searched using the  following key words 
‘pharmaceutical innovations’ ‘digital business 
ecosystems and open innovations’, ‘collaborative 
enterprise networks’, ‘R&Ds and concurrent 
engineering’. Recommended articles related to 
selected papers were also searched and this made rich 
contribution to the literature coverage. The Scholar 
Google search engine (http://scholar.google.com) 
was used to source grey literature as  published by 
international organization such as; the United 
Nations (UN), the World Bank, the International 
Society for Pharmaceutical Engineering (ISPE), the 
International Federation for Information Processing 
(IFIP), Organization for Economic Co-operation and 
Development (OECD), the Pharmaceutical Research 
and Manufacturers of America (PRMA), Global 
Development Network (GDN) and Publication on 
2nd World Open Innovation Conference at Santa 
Clara, CA, Silicon Valley, November 2015 Edition. 
Publications were chosen for review following the 
understated criteria: (1) the study focused on 
collaborative enterprise networks and pharmaceutical 
open innovations, (2) the study focused on 
pharmaceutical R&D ventures that need innovation 
advancement, (3) the study provided insights and 
information about the antecedents and prospects of 
collaborative network among pharmaceutical firms, 
challenges and proposed measure to improve 
pharmaceutical innovation. Following these criteria, 
66 publications between 2000 and 2017 were 
selected. Publications prior to Eli Lilly and 
McKinsey were only retrieved for content checks but 
not included in the review. Also, papers that 
discussed general systems thinking and 
entrepreneurship were excluded from the review. 
 
EVOLUTION OF COLLABORATIVE NETWORK  
 
CNs investigated in Graca and Camarinha-Matos 
(2017) study started as industry cluster. CN as best 
used to accomplish normal and compactible 
objectives are fundamentally bolstered by computer 
networks. This system additionally gives a huge 
commitment to understand the structure and flow of a 
business ecosystem. The term Digital Business 
Ecosystem (DBE), puts a strong highlighting on the 
technological support point of view. The DBE idea 
was basically acquainted as an arrangement 
technique with address the test of accomplishing for 
each industry, sector and region, a compelling 
reception of ICT, in particular empowering Small 
and Medium-sized Enterprises (SMEs) to end up 
plainly more innovative and focused in worldwide 
markets (Nachira, 2002; Briscoe, 2009, 2010). A 
DBE, as portrayed by its applicants is a sub-class of a 
Virtual Organizations Breeding Environment (VBE), 
i.e. a source network of organizations established as a 
long-term strategic alliance is therefore considered as 
multi-agent system (Briscoe, 2010). Altogether, a 
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Collaborative Business Ecosystem (CBE) is 
demonstrated as a community of organizations, 
whose connections are made amid a given period, 
bringing about the arrangement of Virtual 
Organizations (VOs), as indicated by collaborative 
business opportunities (Camarinha-Matos and 
Afsarmanesh, 2008). The expanding evolution and 
utilization of ICT, in particular computer networks, 
and collaboration platforms, have changed the ways 
for making business, which have moved from 
traditional industrial clusters to business ecosystems 
supported by collaborative platforms. The term 
Business Ecosystem was introduced by J. F. Moore 
in the early 90s (Moore, 1993, 1996, 2006; 
Peltoniemi and Vuori, 2004; Graca and Camarinha-
Matos, 2017). 
 
ANTECEDENTS OF COLLABORATIVE NETWORK 
 
From a chronicled viewpoint, three decades have 
formed the ecological conditions for supporting inter-
firms collaboration. The 1990s were portrayed by a 
competitive scene utilizing limited systems, focused 
on making enterprises more proficient in isolation, 
where collaboration activities were mostly centered 
on consenting to arrangements with supply chain 
partners (Camarinha-Matos 2013; Gastaldi et al. 
2015). Through connections, value co-creation 
networks develop from commonly valuable 
connections between individuals, companies and 
investment organizations. A consistent realignment 
of synergistic relationships of people, knowledge and 
assets is required for imperativeness of the ecosystem. 
Prerequisites for responsiveness to changing internal 
and external forces make co-creation an essential 
force in a dynamic innovation ecosystem (Russell et 
al. 2011). The concept of business ecosystem has 
turned out to be conspicuous (Graca and Camarinha-
Matos, 2017). 
Enthusiasm for the Digital Ecosystems research 
originates from an assortment of disciplines, from 
computer, to social, to natural sciences and this 
shows itself in the complex potential applications 
that range from business transactions and virtual 
organizations to e-learning platforms and virtual 
universities. Various characterizing highlights from 
an innovative and socio-economic point of view 
underline the Digital Economy initiative. Our 
advantage is in offering help for long-running 
business transactions and the hidden circulated 
organize models that empower these business 
collaborations ( Razavi et al, 2009). "One cannot 
manage a business on its own, but have to manage an 
entire ecosystem ", said by Power and Jerjian (2001). 
Power and Jerjian (2001) guaranteed that business 
community constitutes of incorporated electronic 
business and their formal definition for a business 
ecosystem is a system of websites occupying the 
world wide web (www) based on the EMH 
formulation (Bof and Previtali, 2007; Kusi et al, 2016) 
together with those aspects of the real world with 
which they interact (Baldwin, 2012). 
It has been identified that IT is one of speed’s critical 
allies (Andersson et al, 2010). Organizations say a 
great deal in regards to day in and day out, 
dependably on world, and IT is the thing that makes 
that conceivable. Presently rising are collaborative 
configuration devices that make it less demanding to 
innovate and increase the speed to advertise on a 
worldwide level. Reciprocally, the improvements on 
Internet of Things, encouraging access to countless 
information sources, empower the appearance of the 
idea of detecting enterprise and the powerful usage of 
better performance measurement mechanisms 
(Osório et al, 2013). Managing IT and innovation is a 
crucial part of the ecosystem equation. More than 
ever before, timing is turning into one more of the 
most vital component of success. The adoption of 
ICT to direct collaboration which facilitates rapid 
solution prototyping and concurrent engineering can 
enable enterprises to enhance their innovation 
capabilities and shorten the measure of time it takes 
to get a product to market (Andersson et al, 2010). 
In the Knowledge Economy, value is never again 
created solely through the traditional value chain; 
most recent business thinking acknowledges the 
critical part of intangibles alongside an intensive 
comprehension of the network dynamics (Allee, 
2000; Razavi et al, 2009). Interest in the value 
network, as opposed to the value chain, had 
expanded and opened up the space for considering 
ideas saw in living beings that show up in 
investigations of biodiversity. In this reasoning, 
enterprises and business connections are displayed as 
living, auto-poietic networks (Razavi et al, 2009). 
Digitization has changed B2C-connections 
fundamentally in style of connected devices and 
computerized networks. This was likewise 
anticipated would be going to influence B2B areas 
altogether later on, since as per an overview led by 
Technology Review the measure of connected 
devices will increase from 17 billion now to 28 
billion by 2020 (Paulus-Rohmer et al., 2016). 
Open Innovation (OI) is seen as the direct inverse of 
the earlier innovation model where vertically 
coordinated firms initiate, research, develop, and 
ultimately commercialize a product from within the 
walls of their own organizations. Critical parts of OI 
incorporate R&D networking, collaboration, 
corporate entrepreneurship, and proactive Intellectual 
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Property (IP) administration. A key idea driving 
hypothesis is that through networking and 
collaboration, innovation can be performed faster, 
more productively, and successfully through the 
exchange of ideas, in actuality enhancing the 
advertising of thoughts to make win– win situations 
for the organizations involved. OI perhaps is 
emerging, which all the more comprehensively 
characterizes it to incorporate stretched out 
networking that enables firms to enhance their 
innovation base in order to exploit societal and 
ecosystem capital and the creative commons at their 
disposal (Chesbrough 2003; 2006; 2010). 
Traditionally, innovation has been to a great extent 
viewed as driven by firm and entrepreneurial 
activities that outcome in the improvement of new 
products, services, and processes. Similarly, 
traditional innovation models have delineated an 
incentive as streaming straightly and consecutively 
from innovation-creating firms to innovation-
adopting ecosystems. However, recent works on OI 
demonstrate direct and successive value stream 
models since it is winding up progressively apparent 
that they are ineffectual in catching the 
interconnected and related nature of the networked 
economy (Nelson and Nelson 2002; Vargo et al. 
2015; Wieland et al, 2016). Frequently in various 
vertical industries, competing ecosystems endeavor 
to innovate faster to catch the most value. In the 
semiconductor industry, there was extraordinary 
competition between the Power PC (Apple, IBM and 
Motorola) and the Intel architecture ecosystem. At 
last the Intel ecosystem won out, to some degree 
because of the faster rate of innovation and broader 
adoption of Intel architecture-based products. In the 
meanwhile, a dynamic opening of the organizations 
limits empowered what has been characterized the 
Open Innovation worldview (Chesbrough 2003; 
Appio et al. 2016), in which remotely engaged, 
synergistic development practices were adopted. 
The collaboration amongst partners and the different 
layers of an enterprise, from marketing to 
infrastructure, has included advantages, but once in a 
while sudden. For instance, American Airlines' 
parent company profited from collaborating with 
different businesses, its reservation system, than it 
produced using the real carrier in the previous decade. 
On the off chance that American Airlines had 
concentrated exclusively on transporting clients, it 
would have passed up a major opportunity for a 
generous measure of income. And the current poster 
child for product ecosystems, Apple, is a magnificent 
case of how concentrating on full integration within 
product ecosystem specifically influences the 
achievement of the organization. On the off chance 
that Apple had not concentrated on making iTunes, 
and building a supporting model, it is potentially that 
the iPod won't not be getting a charge out of the 
notoriety that it has today. Presently, that product 
family has extended beyond gadgets and accomplices 
to incorporate partnerships with firms, for example, 
BMW Company (Andersson et al, 2010). The Tesla 
autos created in Silicon Valley contrast radically 
from traditional automobiles, and their model of 
distribution advances from the standard. In any case, 
there are various elements of this automobile that line 
up with current understandings of autos. The 
introduction of Tesla automobiles has demonstrated 
that even electronic cars keep on being vital images 
for the way of life and budgetary achievement of 
their users. Correspondingly, Tesla achievement, at 
any rate incompletely, has been founded on the 
company’s ability to create an expansive number of 
"charging stations" around the world in a value 
network (Wieland et al, 2016). 
The concept of OI is whereby an organization 
purchases, licenses, or mutually develops new 
products with ecosystem accomplices as opposed to 
depending exclusively without anyone examining is 
vital. Through co-creation, new products can be 
developed speedier and conveyed to market more 
efficiently. Procter and Gamble's (P&G's) Connect 
and Develop technique (Wieland et al, 2016) is an 
extraordinary illustration. CN interfaces people, ideas, 
and technologies to create an OI pipeline that is 
greater and stronger than it may somehow or another 
is. P&G’s aim is to source up to half of new product 
concepts remotely. In spite of the fact that speed and 
R&D don't generally blend, the two can work pair. 
But, when an organization concentrates barely on 
individual product development as most do, it misses 
an open door for innovation and extra income. The 
most elevated returns may really originate from 
different parts of the R&D situation, especially when 
endeavors are focused on creating a successful 
product ecosystem. While arduous in itself, a product 
dispatch ought to be only one portion of a keenly 
considered ecosystem that decides long-term 
achievement and enables enterprises to flourish and 
survive (Andersson et al, 2010; Spolidoro, 2011). 
Medication creators utilize front line science to find 
pharmaceuticals, however they generally 
manufacture these medicines utilizing strategies that 
have not advanced much over the past two decades. 
Emerging technologies through firm collaboration 
can lead to more robust manufacturing processes 
with fewer intrusions, less product disappointments, 
and more noteworthy affirmation that pharmaceutical 
products manufactured will reliably give the normal 
clinical execution. By definition, emerging 
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technologies have two key attributes: curiosity and 
effect. That is, the technology or the application of a 
technology should be considerably novel and 
extraordinary in the pharmaceutical industry, and the 
usage of such an innovation can possibly change the 
ability of the manufacturing sector, along these lines 
enhancing item security and quality. Emerging 
technologies could be an innovative or novel 
(O'Connor et al., 2016). 
 
PROSPECTS OF COLLABORATIVE NETWORK 
 
An understanding of the intricate issues and 
operating patterns in the pharmaceutical industry 
helps to better understand the prospects of 
collaborative networks in the sector. As indicated by 
Scherer (2000), Pharmaceutical industry alludes to 
any mechanical action whose objective is the 
development, production and marketing of 
medications authorized for the utilization as drugs. 
These medications are ordered into various classes in 
view of its origin (synthetic, plant-derived, 
antibiotics, and many others). The pharmaceutical 
industry has several unique characteristics: highly 
globalized and diversified, requiring big investments 
and bringing a tremendous benefit not only for the 
public health but also in terms of economic 
productivity. Pharmaceutical and Biotechnology 
industry in the world contribute right around 15% of 
the aggregate sales value in R&D making them the 
number one sector in R&D speculation (Aamir et 
al.2014). The pharmaceutical industry is knowledge 
intense, and depends on immense R&D investments: 
in spite of pharmaceuticals once developed just 
keeping in mind the end goal to cure maladies, as 
time continued, it had turned out to be increasingly 
an issue of business and a result of the venture. 
Aamir et al (2014) remarked that, there is no industry 
as complex as the pharmaceutical business today, 
with regards to working together and profiting. The 
value chain of the pharmaceutical business is 
intricate, exceptionally reliant on strategies for drugs 
endorsement, and progressively disaggregated, with 
large pharmaceutical firms collaborating in various 
routes with smaller actors (Raja and Sambandan, 
2015). 
In close connection with the value chain in the 
pharmaceutical industry, the idea of R&D efficiency, 
measures the execution of the value chain. R&D 
profitability can be essentially characterized as the 
connection between the value made by another 
medication and the ventures required producing that 
pharmaceutical (Paul et al. 2010). The objective of 
the pharmaceutical business is to find and market 
new medications. In this manner, its foremost action 
is the new medication R&D process. According to 
Sadat et al. (2014), this procedure is organized into 
four consecutive exercises (research, development, 
manufacturing and marketing). This organized 
procedure is therefore termed as pharmaceutical 
innovation value chain. 
 
Figure 1: Pharmaceutical innovation value chain 
Source: Sadat et al., 2014 
Research activity involves the identification and 
validation of new targets which is basically a 
naturally existing cellular or molecular structure that 
the drug in development is meant to act on. 
Development activities: include preclinical 
experimentation of the new molecular entity, NME 
(new drug) in live cells, tissues or animal models to 
demonstrate its safety and effectiveness. The drug 
candidate is then clinically tested to demonstrate its 
safety and efficacy in humans. Regulatory, 
manufacturing and marketing activities: The NME 
which successfully passes through all these stages 
finally goes through approval stage, where it comes 
under the lens of regulatory boards of the place 
where it is to be manufactured and marketed. Such 
newly developed medications are patented by the 
organizations to gain exclusive commercialization 
rights (Sadat et al, 2014). 
Petrova (2014) study also captured a multi-tier 
system of organizations supplementing each other’s 
competencies might be best equipped to handle the 
complexities of modern drug innovation both 
efficiently and effectively. In fact, it has already 
emerged. Three organizational tiers are involved in 
pharmaceutical innovation: public sector 
organizations provide the fundamental science that 
essentially maps out the landscape for subsequent 
innovations, small biotech firms serve as a veritable 
innovation engine, conducting cutting-edge research 
and supplying novel biomolecules, while large 
pharmaceutical firms, ambidextrous and 
multifunctional, are particularly adept to serve as a 
vehicle for advancing scores of drug candidates 
through clinical trials to FDA approval, and then to 
commercialization. These three organizational types 
complement each other’s strengths and can operate in 
symbiosis to advance biomedical research in a 
trifecta model of innovation. 
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Figure 2: The trifecta model of innovation in the 
pharmaceutical industry 
Source: Petrova, 2014 
 
An expanding run-through with regards to 
technology transfers and know-how dissemination 
through firms builds upon the positive impetus made 
by the receptiveness of essential science (Keinz et al, 
2013). Notwithstanding remaining alert to the 
scholarly yield of public sector institutions, 
pharmaceutical firms try to bring down the aggregate 
expenses of new medication creation and abbreviate 
an opportunity to advertise through strategic alliances 
and licensing agreements (Bianchi et al., 2011; 
Dahlander and Gann, 2010). Computed knowledge 
exchanges present system efficiencies by 
manipulating synergies between different resources 
and assets held or created by the individual firms. 
Sharing expertise can encourage and accelerate the 
innovation process and would clarify the regularly 
expanding number of licensing deals, partnerships, 
and strategic alliances among pharmaceutical firms 
(Ihl et al, 2012; Lakhani and Tushmann, 2012). 
Within this context, there is evidence that 
pharmaceutical products created through 
collaborative innovation are essentially more inclined 
to succeed clinical trials. In a specimen overwhelmed 
by firms, Danzon et al. (2005) find that interfirm 
collaboration in clinical trials creates a 15 % more 
prominent likelihood of endorsement contrasted with 
autonomous endeavors. These chances may really be 
old news to the industry as demonstrated by current 
business practices, which demonstrate that contrasted 
with synergistic pharmaceutical firms, single 
pharmaceutical firms are more averse to take 
tranquilize possibility to clinical trials all alone 
(Arora et al. 2007). 
Collaborative pharmaceutical firms are in a position 
to appreciate the vast awareness, credibility, and the 
brand equity that single firms find lacking. 
Attributable to their sizable spending plans and more 
prominent size of operations, collaborative firms are 
ready to have less demanding contact to resources. 
They are additionally more inclined to have the 
fundamental promoting assets single firms may 
discover hard to secure. Likewise, matchless 
resources like an unfaltering notoriety for process 
thoroughness and product quality may end up being 
basic for supporting a competitive edge in swarmed 
treatment markets. Such immaterial resources could 
be all the more effortlessly accruable to collaborative 
firms due to their tremendous creation portfolios and 
long track records of market nearness and innovation. 
As biotech organizations accept the part of famous 
drivers and providers of innovation, those that 
succeed can appreciate a fairly great business 
standpoint. There is exact confirmation that firms 
putting more in research have a tendency to get all 
the more licensing deals. Thus, having a wide 
arrangement of permitting bargains converts into all 
the more new authorizing bargains (Wuyts and Dutta, 
2008). Therefore, interest in centered R&D 
endeavors can make a self-perpetuating momentum 
that bolsters firm feasibility and gets manageable 
income streams from authorizing. Increased 
innovation output, learning impacts, the collection of 
significant R&D stock, or a developing notoriety for 
inventiveness and novelty can clarify these linkages. 
However, discoveries have demonstrated out that a 
convincing reason behind such partnerships is the 
expectation to diversify risk and share huge 
marketing costs for a looming market dispatch. So 
far as that is concerned, strategic alliances are created 
for the express purpose of marketing a particular 
medication mutually. Normally, partner firms utilize 
carefully coordinated pricing and communications 
strategies and, by pooling their business supremacies 
together, can acquire more extensive access to 
market. The integration of external ideas, knowledge, 
technology, or know-how can decide the future 
market alternatives for the collaborative 
pharmaceutical firm, and can be an instrument to 
rapidly adjust an incidentally debilitated pipeline. 
Given the instability in picking up FDA endorsement 
with a solitary medication applicant, a wealthier 
portfolio will build the collaborative firm’s odds to 
take not less than one drug to market. The 
accomplishment of a plan of business with a stouter 
inclining toward external innovative input through 
in-licensing might be dependent upon the present 
condition of the firm's R&D portfolio, and in 
addition its ability to draw in, select, and do 
undertakings of more prominent potential for 
progress (Danzon et al, 2005; Grewal et al. 2008; 
Valle and Va'zquez-Bustelo, 2009 ). 
Several operational models of OI have been 
recognized in the large and collaborated 
pharmaceutical ventures. Models had been 
established based upon the level of openness of a 
company considering two factors that were focusing 
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on the externally acquired innovation as is defined by 
all the R&D projects along the clinical development 
phase of the Pharmaceutical innovation value chain 
acquired from outside the company. Here anyway we 
should take note of that the preclinical stages have 
not been mulled over for setting up those models. 
The resulting factor considered the choices of 
innovation management. Here the choice of 
innovation management fundamentally mirrors the 
strategic decision made by the organization in 
dealing with their innovation which could be either 
prevalently inward or transcendently outward. By 
examining a portion of the large pharmaceutical 
industries under the components specified over, four 
distinct sorts of OI models were additionally 
recognized, the knowledge creators, the knowledge 
integrators, the knowledge translators and the 
knowledge leveragers (Hu et al, 2007; Schuhmacher 
et al, 2013). 
In the knowledge creator model (Judd, 2013), the 
R&D endeavors gained are for the most part through 
university partnership or collaborations which are 
utilized as a supplement for the inside completed 
standard R&D projects, which are additionally 
created utilizing as a part of domestic talents and 
resources. Though in the knowledge integrator model 
the greater part of the R&D ventures are gained or in-
licensed through superficial sources and created and 
oversaw additionally utilizing the mastery of the 
organization's internal assets. The third model, the 
knowledge translator model is fundamentally the 
same as the knowledge creator model however aside 
from the way that it utilizes outsourcing and 
collaboration as an instrument to deal with their 
R&D venture productively keeping in mind the end 
goal to lessen cost or utilize the specialization or 
specialized abilities of the outer sources to take the 
R&D activities to the subsequent stage. The fourth 
model which is the knowledge leverager model is 
once in a while found practically speaking with not 
very many enterprises in the Pharmaceutical industry 
actualizing it (Raja and Sambandan, 2015). In this 
model larger part of the innovation is caused from 
outside that is drug candidates, technological know-
hows, specialized abilities are obtained from outer 
sources to increase most extreme advantage out of 
the inside accessible assets, assist the innovation is 
masterminded through practically "virtual network" 
by broad collaborations (Kim and West, 2014). 
Joint laboratories are related with collaboration on 
graded level as the two crowds even meet inside a 
similar lab. Strategic partnerships depend on a close-
interaction model because of their typical 
concentration on numerous activities and the 
deliberate facets endeavor. Consortia, joint research 
or crowdsourcing are regularly in view of individual 
activities and include a minor particular portion of 
the organization temporarily period. Outsourcing or 
licensing activities is depicted as a progress of 
resources with diminishing authoritative contribution, 
and incubator concepts are normally directed "at a 
manageable distance" (Lakhani and Tushmann 2012). 
 
CHALLENGES 
Despite the fact that collaboration can be good to 
share risks, it converts likewise important to 
anticipate and handle different types of risks and 
perceived risks by collaboration partners. 
Relationship risks can even turn allies into rivals 
(Wieland et al, 2016). Open innovation tools and 
inter-firm collaboration clearly incorporate different 
risks for the involved parties, for example when 
stronger parties abuse their potentials more than one 
or a multitude number of smaller accomplices 
(Gomes-Casseres, 2000; Powell et al., 2002; Lawler, 
2003; Tamoschus et al, 2015). All things considered, 
excessively limit a specialization in innovation can 
end up plainly unsafe as economies of scope may be 
rare. In addition, overreliance on partnerships and 
exorbitant reliance on collaboration, essential to rout 
the requirements of tight specialization, can turn 
problematic. Contradictions between accomplices 
may happen, prompting delays. The experienced 
R&D expenses can be hard to assign and recover 
(Bullinger et al., 2012; Kuenne et al., 2011). More 
proficient management of conglomerates (Lessl and 
Douglas, 2010) is fundamental as sorts of knowledge 
and the exploration and amalgamation mechanisms 
for knowledge (Almirall and Casadeus-Masanell, 
2010; Laursen and Salter, 2006) change in a more 
complex innovation scene, conceivably expanding 
the expenses of assimilation and making open 
innovation management multifaceted. 
Another enormous class of results of the efficient 
emergency alludes to the adjustment in the structure 
of the industry that intends to reverse the spending 
limitations and limit the expanding risk: the value 
chain of the R&D structure is currently more 
disaggregated, with various actors involved at 
various stages. In this manner, the collaboration 
firms do not retain the entire R&D process any 
longer, and are adjusting their procedures to be more 
organized, collaborated and utilized from a 
completely incorporated model (Paul et al. 2010). 
However there have been various difficulties as for 
the appropriation of OI, Standardization of the 
process, Management troubles as for virtually 
dispersed R&D, boost, absence of authority, 
governance, specialized do-capacity, loss of 
compositional knowledge (Lowman et al, 2012). OI 
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likewise represents a requirement for cultural change 
inside the organization and configuration of the 
general business system with the OI process. Firms 
ought to equally reexamine their plan of action and 
furthermore can pick the exact collaboration model 
(Raja and Sambandan, 2015). 
Firms seeking licensing or acquisition targets may 
need to locate the correct harmony between utilizing 
particular capabilities and accomplishing pipeline 
diversity. Measuring the knowledge-based assets of 
different firms can be fairly difficult. Just firms 
effectively occupied with certain restorative ranges 
may have the certainty and the abilities to precisely 
evaluate the capability of others' R&D endeavors, the 
skill to deal with the development technique all the 
more proficiently, or the advertising background and 
the business contacts to execute the launch 
adequately. Actually, gaining a firm with a slightly 
extraordinary pipeline may be beneficial in its own 
particular perfectly fine will add to the obtaining 
firm’s project discrepancy. Keeping up engaged or 
broadened examine portfolios might be differentially 
helpful for single versus collaborative firms (Keinz et 
al, 2013; Ihl et al, 2012; Lakhani and Tushmann, 
2012). Additionally, better management of 
intellectual property (IP) and the particular abilities 
to make an interpretation of research into commerce 
products or coordinate new technologies and 
processes into development is significant to the 
innovativeness (Vertes, 2012). 
For the most part, single firms would discover 
collaborative firms appealing to band together with 
as a result of their impressive assets and intangible 
assets. However, in a partnership, collaborative firms 
should share the possible market earnings with 
another firm. On the off chance that solitary firms 
can profit by the prompt access to subsidizing, 
downstream resources, and experience that 
cooperation with collaborative firms make 
conceivable. For them, in-licensing is an alternate 
way to rapidly fill their product pipelines and 
broaden their research portfolios. As constant 
innovation is very essential in the pharmaceutical 
industry, recharging drug pipelines all the time is 
pivotal for keeping up a strong competitive 
advantage (Lessl and Douglas, 2010). Collaborative 
pharmaceutical firms are under steady strain to keep 
up full and promising venture portfolios, which 
makes them alluring to investors and can influence 
these firms' entrance to wealth. Ultimately, all the 
more subsidizing is required especially for the 
scholarly world and scholastic turn offs (Klein et al, 
2009), frequently bringing about co-development 
activities inside the networks and ecosystems of 
venture resources (Vertes, 2012). 
Petrova (2014) distinguished that proprietorship and 
sharing of assets is a customary trouble with 
collaborative firms, regardless of whether it identifies 
with assets got by individuals or assets gained by the 
coalition with the end goal of playing out the errand. 
Moreover, finding a reasonable method for deciding 
the individual commitments to a joint protected 
innovation creation is a legitimately difficult issue. IP 
creation is not straightly identified with the extent of 
assets contributed by each partner. At the extremely 
base of this issue is the need to achieve a typical 
impression of the merchandized values, which 
requires the meaning of a benefits model and an 
arrangement of motivations, in view of a typical 
value system. An ordinary sensation in cumulative 
efforts is the weakening of duty. A successful 
collaboration relies on sharing the obligations, both 
amid the way toward accomplishing the objective 
and furthermore the liabilities after the completion of 
the cooperation. Regularly winds up plainly 
troublesome in sharing project responsibilities. 
 
CONCLUSION  
With the consideration of tremendous application of 
the CNs by other industrial sectors, it has been 
realized that virtual and networked firms have been 
benefiting from collaborations for a decade now. OI 
results competitive advantage and value creation that 
projects collaborative enterprises to the upper limit 
for both local and international market shares. In the 
pharmaceutical industry are competencies and 
disciplines that mechanize innovation for new drug 
creation as well as shortening market lead times. Co-
created drugs are more likely to succeed clinical 
trials. Vast awareness, credibility and the brand 
equity are other derivatives of strategic alliances 
among firms. The absence of preclinical activities, 
choices of innovation management, overreliance and 
many others are critical ailments that are affecting 
the pharmaceutical inter-firm collaboration health. 
The study therefore identified a lag for concurrent 
engineering that enhances rapid prototyping for 
parallel new drug creation and production. 
Pharmaceutical industries are to be assumed 
incentives and subventions for growth and 
advancement. Interdependency and efficient R&D 
capabilities with corporate support for new drug 
research are similarly crucial for sustainability. 
Therefore connectivity between domestic research 
institutes and the drug manufacturing firms with 
effective IP rights to protect open collaborative 
innovation is vital. CN provides VBE that facilitates 
virtual laboratory which prepares platform for 
concurrent engineering that result simultaneous 
product co-creation. 
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